Publications by authors named "Ariane Lappara"
Background: Immune checkpoint inhibitors (ICI) have transformed cancer treatment over the last decade. Alongside this therapeutic improvement, a new variety of side effects has emerged, called immune-related adverse events (irAEs), potentially affecting any organ. Among these irAEs, myocarditis is rare but life-threatening.
View Article and Find Full Text PDFArticle Synopsis
- A recent observational study examined the link between immune-related adverse events (irAEs) and survival in patients with non-small cell lung cancer (NSCLC) and melanoma undergoing treatment with immune checkpoint blockers (ICBs), addressing previous issues related to immortal-time bias.
- The study included 577 patients and found that the occurrence of irAEs was significantly linked to improved overall survival (OS) and progression-free survival (PFS), indicating a favorable effect of such adverse events on patient outcomes.
- The findings reinforce the notion that while irAEs may be challenging, they could be indicative of a more effective treatment response in patients receiving anti-PD-(L)1 antibodies.
Purpose: We investigated the activities of an ImmunoTOX board, an academic, multidisciplinary group of oncologists and organ specialists that adopts a real-life, case-by-case approach in the management of patients with immune-related adverse events (irAEs).
Experimental Design: The ImmunoTOX assessment board was set up in 2016 at Gustave Roussy in France. It meets every 2 weeks to discuss the case-by-case management of patients presenting with irAEs.